Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Fulwel
Fulwel Fulvestrant 250 mg is a hormonal therapy used to treat hormone receptor-positive breast cancer in postmenopausal women. It is an injectable therapy that works by targeting estrogen receptors on cancer cells. Fulvestrant blocks estrogen signaling and leads to the degradation of estrogen receptors, inhibiting tumor growth. Fulwel is particularly beneficial for patients who have progressive disease or those whose tumors are resistant to other hormone therapies like tamoxifen. By lowering estrogen-driven cell proliferation, Fulwel offers an effective treatment option for managing advanced breast cancer.
Uses of Fulwel
Fulwel is indicated for:
Hormone Receptor-Positive Breast Cancer in Postmenopausal Women
Treatment of Advanced or Metastatic Breast Cancer
For Patients Progressing on Other Hormonal Therapies
Benefits of Fulwel
Targeted Action to Block Estrogen's Effect on Cancer Cells
Reduces Tumor Growth by Degrading Estrogen Receptors
Proven Effective for Advanced and Metastatic Breast Cancer
Administered via Intramuscular Injection for Convenient Monthly Dosing
Used for Patients Resistant to Other Hormonal Treatments
Well-Tolerated with Minimal Systemic Side Effects
Mechanism of Action of Fulwel
Fulwel is a selective estrogen receptor degrader (SERD) that works by binding to estrogen receptors on the surface of cancer cells. This binding blocks estrogen from activating the receptors and triggers the degradation of the receptor. Without functional estrogen receptors, cancer cells are unable to grow and divide in response to estrogen. Fulwel thus impairs the tumor’s ability to grow, making it an effective therapeutic option for managing hormone receptor-positive breast cancer in postmenopausal women.